AnaptysBio (ANAB) Swings Back To Q1 Loss Per Share Challenging Recent Profitability Hopes

AnaptysBio (ANAB) just posted its Q1 2026 update with total revenue of US$25.6 million and a basic EPS loss of US$1.84, alongside a net loss of US$52.9 million, setting a clear tone for how the new year is starting after a profitable Q4 2025. Over recent quarters, revenue has moved between US$22.3 million and US$108.2 million while basic EPS has swung from a profit of US$1.79 per share in Q4 2025 to losses such as US$1.34 in Q2 2025, so the latest figures land against a backdrop of uneven top line and earnings. For investors, a central consideration from this update is whether current revenue levels are sufficient to support improved margins over time as the story develops.

See our full analysis for AnaptysBio.

With the latest numbers on the table, the next step is to see how this earnings profile compares with the widely followed narratives around growth potential, risks, and the path toward profitability.

Curious how numbers become stories that shape markets? Explore Community Narratives

Losses Persist With US$26.8 Million LTM Net Loss

• On a trailing twelve month basis, AnaptysBio recorded total revenue of US$232.4 million and a net loss of US$26.8 million, with trailing EPS at a loss of US$0.95 per share.
• What stands out for a bullish view that focuses on growth is that the same data set pairs these losses with revenue growth forecasts of 23.7% per year and earnings growth forecasts of 46.33% per year, which:
  • Supports the idea that the business model is being built around scaling revenue, but also highlights that the path to profitability in those forecasts contrasts with the current US$26.8 million loss.
  • Means anyone leaning bullish has to be comfortable that the move from a loss of US$0.95 per share to positive earnings is based on projections rather than what the recent twelve month figures alone show.

Five Year Loss Widening Meets 7.8x P/S Discount

• The company is trading on a P/S of 7.8x, which is below both the US biotech industry average of 9.7x and a peer average of 29x, even though reported losses have increased at about 10.8% per year over the past five years.
• Bears often point to that 10.8% annual widening in losses as a concern, and the figures here give that view some backing, but the lower 7.8x P/S multiple creates a tension with that cautious stance because:
  • The valuation discount relative to the 9.7x industry and 29x peer averages suggests the share price already reflects some of that multi year loss trend.
  • At the same time, the fact that losses have continued to widen over five years means the lower P/S is not being paired with trailing profitability, which is exactly the kind of set up critics focus on.

DCF Fair Value Far Above US$62.69 Share Price

• The current share price of US$62.69 sits far below a cited DCF fair value estimate of about US$348.31. Forecasts in the same analysis point to revenue growth of 23.7% and earnings growth of 46.33% per year, with profitability expected within three years.
• Supporters of a bullish case often highlight that large gap between price and DCF fair value, and these figures heavily support that angle on paper. Yet the data also remind you of important frictions in the story because:
  • Trailing twelve month results still show a net loss of US$26.8 million, so the DCF fair value of US$348.31 is being justified by future projections rather than current profitability.
  • Recent commentary also flags short term share price volatility and significant insider selling over the past three months, which sits awkwardly next to any argument that the stock should trade closer to that DCF figure.

Bulls and skeptics are looking at the same US$62.69 share price and very different futures, so it is worth seeing how those cash flow and growth assumptions are laid out in detail in the full narrative 📊 Read the what the Community is saying about AnaptysBio.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on AnaptysBio's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With a mix of risks and potential rewards running through this story, the most helpful next step is to review the figures yourself and decide how they stack up for your goals, then round out that view with 2 key rewards and 2 important warning signs

See What Else Is Out There

AnaptysBio is still reporting losses on a trailing basis, with widening five year losses and insider selling sitting against a P/S discount and optimistic forecasts.

If that mix of ongoing losses and forecast driven optimism feels a bit too dependent on projections, it is worth comparing with companies filtered through the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com